While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing for future product approvals.

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical ... applications for depemokimab have been accepted for review by the China National Medical (TASE:PMCN) Products Administration and submitted ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

Banco Santander (BME: SAN) shares spiked over 6% on Wednesday after the lender unveiled plans for €10 billion (£8.3 billion) ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications for depemokimab ...